Curative Effect of Lenvatinib Combined with Locoregional Therapy on PD-L1-positive Hepatocellular Carcinoma Patients with Type Ⅰ-Ⅲ Portal Vein Tumor Thrombus According to Cheng's Classification
10.3971/j.issn.1000-8578.2022.21.0794
- VernacularTitle:仑伐替尼联合局部疗法治疗PD-L1基因阳性门脉癌栓程氏分型Ⅰ~Ⅲ型肝癌疗效观察
- Author:
Long CHEN
1
;
Yujie LIU
;
Suqing TIAN
;
Cuiying WANG
;
Donglei HE
Author Information
1. Department of Oncology, Sanya Central Hospital, The Third People's Hospital of Hainan Province, Sanya 572000, China
- Publication Type:Research Article
- Keywords:
Hepatocellular carcinoma;
Lenvatinib;
Locoregional therapy;
Portal vein tumor thrombus;
PD-L1
- From:
Cancer Research on Prevention and Treatment
2022;49(1):53-57
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare curative effect between lenvatinib combined with locoregional therapy and locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng's classification. Methods The patients in lenvatinib combined with locoregional therapy group received orally-administered lenvatinib at a dose of 12 mg qd for patients≥60 kg or 8 mg qd for patients < 60 kg. The locoregional therapy group only received locoregional therapy. We retrospectively analyzed the clinical data and prognosis of two groups. Results The CR+PR were 78.1% and 53.6% in the combination group and locoregional therapy group, respectively (P < 0.05). The response rate, disease control rate and overall survival of the combination group were higher than those in the locoregional therapy group (P < 0.05). Conclusion The curative effect and overall survival of lenvatinib combined with locoregional therapy is better than locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng's classification.
